Source/Disclosures
Source:

Healio Coverage

November 21, 2020
1 min read
Save

Eight important updates for Pancreatic Cancer Awareness Month

Source/Disclosures
Source:

Healio Coverage

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

November is Pancreatic Cancer Awareness Month.

The observance is intended to raise awareness about the disease and the need for more effective therapies.

Metastatic cancer of the pancreas.
Source: Adobe Stock.

In conjunction with the observance, Healio and HemOnc Today present the following eight updates in pancreatic cancer research and treatment.

  • Recent-onset diabetes accompanied by weight loss appeared to be associated with a substantially higher risk for developing pancreatic cancer. Read more.
  • Alexander Raufi, MD, explores how genomics, proteomics, metabolomics and in-depth analyses of the tumor immune microenvironment have uncovered new therapeutic targets for which promising novel agents are being tested. Read more.
  • A liquid biopsy has shown promise for the early detection and staging of pancreatic ductal adenocarcinoma. Read more.
  • NantKwest and ImmunityBio have partnered on a phase 2 trial to examine the efficacy and safety of a chemoimmunotherapy regimen for treatment of metastatic or locally advanced pancreatic cancer. Read more.
  • Increases in the proportion of patients diagnosed with pancreatic cancer at an earlier stage and younger age may be due to improvements in early detection and diagnosis. Read more.
  • A precision medicine approach to therapy significantly extended survival for patients with pancreatic cancer compared with standard chemotherapy. Read more.
  • Researchers developed an enzyme-targeting drug that could prolong survival for patients with metastatic pancreatic cancer. Devimistat (CPI-613, Rafael Pharmaceuticals) will be evaluated in combination with modified FOLFIRINOX in a phase 3 clinical trial. Read more.
  • Men with a family history of pancreatic cancer should be tested for hereditary cancer genes to guide surveillance and screening strategies for prostate cancer, according to recommendations developed at a multidisciplinary consensus conference. Read more.